GLP-1 progress ratings on TikTok: fun trend or false benchmarks?

What's this video probably claiming?

Based on the hashtags and caption, @jameskosiba is almost certainly participating in one of the recurring GLP-1 community trends on TikTok where users rate their own progress, side effect tolerance, or overall experience on semaglutide or tirzepatide using some kind of scoring format. The "how do you rate yours?" framing suggests a self-assessment template, likely covering things like weight loss results, nausea severity, appetite suppression, or injection experience. These kinds of videos are enormously popular in the Wegovy and Mounjaro communities because they give people a shorthand way to compare experiences. The problem is that personal ratings, however entertaining, quietly set expectations about what a "good" or "normal" GLP-1 response looks like. When your experience doesn't match the person on your screen, that gap can drive unsafe behavior like dose escalation, medication switching, or abandoning treatment entirely before it has a real chance to work.

What does the science actually show?

Clinical trial data makes one thing very clear: response to GLP-1 receptor agonists varies enormously between individuals, and that variation is not a sign of failure. The STEP 1 trial (Wilding et al., 2021, NEJM) showed semaglutide 2.4mg producing a mean weight loss of 14.9% over 68 weeks, but the range within that cohort was wide. Some participants lost over 20% of body weight; others lost closer to 5%. Tirzepatide data from the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed even broader spread, with the 15mg dose producing mean weight loss of 20.9%, but again with meaningful individual variation. Genetics, baseline metabolic health, gut microbiome composition, and adherence all influence outcomes in ways no TikTok rating scale captures. The side effect picture is equally variable. Nausea affects roughly 44% of semaglutide users at some point during treatment per clinical trial data, but severity and duration differ sharply from person to person.

Where does the social media noise diverge from clinical reality?

The GLP-1 TikTok ecosystem has a selection bias problem that nobody in the community talks about openly. The people making rating videos are, by definition, people who are still on the medication, still engaged enough to post, and motivated enough to present a scorecard. You are not hearing from the people who stopped because of intractable nausea, the people whose insurance denied a refill, or the people whose weight loss plateaued at week 12 and never resumed. Research on online health communities consistently shows that positive and dramatic outcomes are over-represented in user-generated content. When a rating trend implies that a score of 8 or 9 out of 10 is normal, it creates a reference point that is skewed heavily toward the best-case end of the actual distribution. Clinicians treating GLP-1 patients report that unrealistic social media benchmarks are increasingly showing up in consultations, with patients questioning their treatment based on comparisons to online influencers rather than their own clinical trajectory.

What should you actually know?

If you are on semaglutide or tirzepatide and you feel like your results do not match what you are seeing on TikTok, the most useful thing you can do is talk to the prescribing clinician, not adjust your own expectations downward based on someone else's show reel. Dose titration schedules exist for a reason. The standard semaglutide protocol escalates from 0.25mg weekly up to a maintenance dose over several months precisely to let your GI system adapt and to find the minimum effective dose for your body. Rushing that process because someone else is further along is how you end up with preventable side effects. The STEP and SURMOUNT trials were 68 weeks long. Most TikTok progress checks are happening at weeks 4 through 16. Meaningful weight loss data in these trials generally accumulated over a much longer window. Community solidarity in the GLP-1 space is genuinely valuable. Peer support improves adherence. But a rating system optimized for engagement is not a clinical benchmark, and treating it like one is where the real risk lies.